Suppr超能文献

免疫疗法新方向。

New directions in immunotherapy.

机构信息

Department of Medicine, Nova Southeastern University, Davie, FL, USA.

出版信息

Curr Allergy Asthma Rep. 2013 Apr;13(2):178-95. doi: 10.1007/s11882-012-0335-7.

Abstract

Allergen immunotherapy (AIT) is effective in reducing the clinical symptoms associated with allergic rhinitis, asthma and venom-induced anaphylaxis. Subcutaneous (SCIT) and sublingual immunotherapy (SLIT) with unmodified allergen extracts are the most widely prescribed AIT regimens. The efficacy of these 2 routes appears comparable, but the safety profile with SLIT is more favorable allowing for home administration and requiring less patient time. However, both require that the treatment is taken regularly over several years, e.g., monthly in a supervised medical setting with SCIT and daily at home with SLIT. Despite the difference in treatment settings, poor adherence has been reported with both routes. Emerging evidence suggests that AIT may be effective in other allergic conditions such as atopic dermatitis, venom sting-induced large local reactions, and food allergy. Research with oral immunotherapy (OIT) for food allergies suggest that many patients can be desensitized during treatment, but questions remain about whether this can produce long term tolerance. Further studies are needed to identify appropriate patients and treatment regimens with these conditions. Efforts to develop safer and more effective AIT for inhalant allergies have led to investigations with modified allergens and alternate routes. Intralymphatic (ILIT) has been shown to produce long-lasting clinical benefits after three injections comparable to a 3-year course of SCIT. Epicutaneous (EPIT) has demonstrated promising results for food and inhalant allergies. Vaccine modifications, such as T cell epitopes or the use of viral-like particles as an adjuvant, have been shown to provide sustained clinical benefits after a relatively short course of treatment compared to the currently available AIT treatments, SLIT and SCIT. These newer approaches may increase the utilization and adherence to AIT because the multi-year treatment requirement of currently available AIT is a likely deterrent for initiating and adhering to treatment.

摘要

变应原免疫疗法(AIT)可有效减轻过敏性鼻炎、哮喘和毒液引起的过敏反应的临床症状。未修饰变应原提取物的皮下(SCIT)和舌下免疫疗法(SLIT)是最广泛应用的 AIT 方案。这两种途径的疗效似乎相当,但 SLIT 的安全性更好,允许在家中进行治疗,且患者所需时间更少。但是,这两种治疗方法都需要在数年时间内定期进行治疗,例如,SCIT 每月在监督医疗环境下进行,SLIT 则每天在家中进行。尽管治疗环境不同,但两种方法都存在治疗依从性差的报道。新出现的证据表明,AIT 可能对其他过敏性疾病有效,如特应性皮炎、毒液蜇伤引起的局部大反应和食物过敏。口服免疫疗法(OIT)治疗食物过敏的研究表明,许多患者在治疗期间可以脱敏,但仍存在疑问的是,这是否可以产生长期耐受。需要进一步的研究来确定这些疾病的合适患者和治疗方案。为了开发更安全有效的吸入性变应原 AIT,人们已经对修饰变应原和替代途径进行了研究。淋巴内(ILIT)已被证明在三次注射后可产生与 SCIT 三年疗程相当的长期临床获益。经皮(EPIT)已证明在食物和吸入性过敏方面有很好的效果。疫苗修饰,如 T 细胞表位或使用病毒样颗粒作为佐剂,与目前可用的 AIT 治疗方法(SLIT 和 SCIT)相比,在相对较短的疗程后即可提供持续的临床获益。与目前可用的 AIT 治疗方法(SLIT 和 SCIT)相比,这些较新的方法可能会增加 AIT 的利用率和依从性,因为目前可用的 AIT 多需要多年的治疗,这可能会阻止人们开始和坚持治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验